Taken together, these findings reveal a novel mechanism of drug resistance and provide the preclinical rationale to developstrategies that target the non-canonical Aurora-A/SMAD5 oncogenic axis and restore chemosensitivity in breast cancer cells. Here, SMAD5 is linked to breast carcinoma.